Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Asia Pacific Influenza Treatment Market By Drug Class, By Route of Administration, By Distribution Channel, and Country
Asia Pacific Influenza Treatment Market size was valued at US$ 3,963.1 million in 2023, growing at a CAGR of 7.1% during the forecast period 2024 - 2030. The global market provides a detailed overview and which can be segmented by drug class, route of administration, and distribution channel. By drug class, the Asia Pacific influenza treatment market has been segmented into anti-viral drugs, interferons, and vaccines. By drug class, the vaccines segment held the largest revenue share of the Asia Pacific influenza treatment market in past years and is expected to have the fastest growth rate over the forecasted period due to the increasing demand for vaccines among a large mass population due to increasing incidences of influenza diseases. By route of administration, the Asia Pacific influenza treatment market has been segmented into oral, parenteral, and others. By route of administration, the oral segment held the largest revenue share market in the past few years and is projected to have the fastest growth rate over the forecasted period due to easy accessibility, and minimum pain.Based on the distribution channel, the segment has been segregated into hospital pharmacies, retail pharmacies, and others. The retail pharmacy segment gained the largest market share in 2022, owing to factors such as the rise in the number of retail pharmacies across the globe. Additionally, some other factors such as a rise in awareness related to the use of influenza drugs further contribute to the growth of the market. Furthermore, the easy availability of influenza drugs surges in the number of retail pharmacies across the globe which further helps to expand the market globally.
The Asia Pacific Influenza Treatment Market Key Development:
Rising incidences of influenza, increasing awareness, and requirement for new drugs and treatment amid the COVID-19 pandemic. Furthermore, a surge in healthcare expenditure and a rise in R&D investments related to ant-viral drugs boost the influenza treatment market growth. For instance, in 2018, F. Hoffmann-La Roche AG launched Xofluza (Baloxavir Marboxil) for the treatment of influenza.
Report Benchmarks |
Details |
Market Size in 2023 |
US$ 3,963.1 million |
By Drug Class |
|
By Route Administration |
|
By Distribution Channel |
|
Download Free Sample Report
The global Asia Pacific influenza treatment market size is expected to grow at a CAGR of 7.1% during the forecast period 2024 - 2030
New product launches, and rising research and development activities for the treatment of influenza diseases with reasonable cost.
Investment and acquisition are the two key strategies opted for by the leading players in the market.
The major factors driving the market growth are the rising incidence of influenza cases among a large mass of the population.
1.Executive Summary |
2. Asia Pacific Influenza Treatment Market Introduction |
2.1. Asia Pacific Influenza Treatment Market - Taxonomy |
2.2. Asia Pacific Influenza Treatment Market - Definitions |
2.2.1.Drug Class |
2.2.2.Route Administration |
2.2.3.Distribution Channel |
2.2.4.Country |
3. Asia Pacific Influenza Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Asia Pacific Influenza Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Asia Pacific Influenza Treatment Market By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Anti-viral drugs |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Zanamivir |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Oseltamivir |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Amantadine |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Rimantadine |
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Others |
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Interferons |
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
5.8. Vaccines |
5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.8.3. Market Opportunity Analysis |
5.9. Trivalent |
5.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.9.3. Market Opportunity Analysis |
5.10. Quadrivalent |
5.10.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.10.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.10.3. Market Opportunity Analysis |
6. Asia Pacific Influenza Treatment Market By Route Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Oral |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Anti-viral drugs |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Parenteral |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Interferon alfa-2b |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Others |
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
7. Asia Pacific Influenza Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospital pharmacies |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail pharmacies |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Others |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Asia Pacific Influenza Treatment Market By Country, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. China |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. India |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Australia and New Zealand (ANZ) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Japan |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Rest of APAC |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.China Influenza Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Anti-viral drugs |
9.1.2.Zanamivir |
9.1.3.Oseltamivir |
9.1.4.Amantadine |
9.1.5.Rimantadine |
9.1.6.Others |
9.1.7.Interferons |
9.1.8.Vaccines |
9.1.9.Trivalent |
9.1.10.Quadrivalent |
9.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oral |
9.2.2.Anti-viral drugs |
9.2.3.Parenteral |
9.2.4.Interferon alfa-2b |
9.2.5.Others |
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital pharmacies |
9.3.2.Retail pharmacies |
9.3.3.Others |
10.India Influenza Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Anti-viral drugs |
10.1.2.Zanamivir |
10.1.3.Oseltamivir |
10.1.4.Amantadine |
10.1.5.Rimantadine |
10.1.6.Others |
10.1.7.Interferons |
10.1.8.Vaccines |
10.1.9.Trivalent |
10.1.10.Quadrivalent |
10.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oral |
10.2.2.Anti-viral drugs |
10.2.3.Parenteral |
10.2.4.Interferon alfa-2b |
10.2.5.Others |
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital pharmacies |
10.3.2.Retail pharmacies |
10.3.3.Others |
11.Australia and New Zealand (ANZ) Influenza Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Anti-viral drugs |
11.1.2.Zanamivir |
11.1.3.Oseltamivir |
11.1.4.Amantadine |
11.1.5.Rimantadine |
11.1.6.Others |
11.1.7.Interferons |
11.1.8.Vaccines |
11.1.9.Trivalent |
11.1.10.Quadrivalent |
11.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oral |
11.2.2.Anti-viral drugs |
11.2.3.Parenteral |
11.2.4.Interferon alfa-2b |
11.2.5.Others |
11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital pharmacies |
11.3.2.Retail pharmacies |
11.3.3.Others |
12.Japan Influenza Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Anti-viral drugs |
12.1.2.Zanamivir |
12.1.3.Oseltamivir |
12.1.4.Amantadine |
12.1.5.Rimantadine |
12.1.6.Others |
12.1.7.Interferons |
12.1.8.Vaccines |
12.1.9.Trivalent |
12.1.10.Quadrivalent |
12.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oral |
12.2.2.Anti-viral drugs |
12.2.3.Parenteral |
12.2.4.Interferon alfa-2b |
12.2.5.Others |
12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital pharmacies |
12.3.2.Retail pharmacies |
12.3.3.Others |
13.Rest of APAC Influenza Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Anti-viral drugs |
13.1.2.Zanamivir |
13.1.3.Oseltamivir |
13.1.4.Amantadine |
13.1.5.Rimantadine |
13.1.6.Others |
13.1.7.Interferons |
13.1.8.Vaccines |
13.1.9.Trivalent |
13.1.10.Quadrivalent |
13.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oral |
13.2.2.Anti-viral drugs |
13.2.3.Parenteral |
13.2.4.Interferon alfa-2b |
13.2.5.Others |
13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital pharmacies |
13.3.2.Retail pharmacies |
13.3.3.Others |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.AstraZeneca |
14.2.2.Hoffmann-La Roche |
14.2.3.GlaxoSmithKline Plc. |
14.2.4.Novartis AG |
14.2.5.Sanofi Pasture |
14.2.6.Protein Sciences Corporation |
14.2.7.Emergent Biosolutions |
14.2.8.BioCryst Pharmaceuticals.Inc. |
14.2.9.Shionogi Inc. |
14.2.10.Abbott Laboratories Inc. |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players